These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34304441)

  • 1. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
    Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
    Diao B; Yang P
    Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
    Zhu S; Bao H; Zhang MC; Liu H; Wang Y; Lin C; Zhao X; Liu SL
    BMC Cancer; 2022 Jun; 22(1):662. PubMed ID: 35710397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
    Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
    J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
    Li W; Huang L; Qi N; Zhang Q; Qin Z
    BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
    Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
    J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Integrated Bioinformatic Approach Reveals the Prognostic Significance of LRP1 Expression in Ovarian Cancer.
    Wolde T; Bhardwaj V; Reyad-Ul-Ferdous M; Qin P; Pandey V
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
    Li Y; Li L
    J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
    Zuo L; Li X; Tan Y; Zhu H; Xiao M
    J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.
    Lin L; Nong W; Luo B; Ge Y; Zeng X; Li F; Fan R; Zhang Q; Xie X
    Immun Inflamm Dis; 2021 Dec; 9(4):1759-1770. PubMed ID: 34528758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer.
    Hou L; Zhang X; Jiao Y; Li Y; Zhao Y; Guan Y; Liu Z
    Medicine (Baltimore); 2019 May; 98(19):e15698. PubMed ID: 31083274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
    Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
    J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.
    Jia W; Chang B; Sun L; Zhu H; Pang L; Tao L; Zou H; Du J; Dong Y; Qi Y; Jiang J; Liang W; Li F; Zhao X
    Int J Clin Exp Pathol; 2014; 7(9):5940-9. PubMed ID: 25337238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analyses and Experiments Confirmed IGFBP5 as a Prognostic Predictor Based on an Aging-genomic Landscape Analysis of Ovarian Cancer.
    Fan TY; Xu LL; Zhang HF; Peng J; Liu D; Zou WD; Feng WJ; Qin M; Zhang J; Li H; Li YK
    Curr Cancer Drug Targets; 2024; 24(7):760-778. PubMed ID: 38018207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
    Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
    J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer.
    Lu W; Xie B; Tan G; Dai W; Ren J; Pervaz S; Li K; Li F; Wang Y; Wang M
    Front Endocrinol (Lausanne); 2023; 14():1088944. PubMed ID: 36742380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.
    Duan C; Li K; Pan X; Wei Z; Xiao L
    BMC Cancer; 2023 May; 23(1):489. PubMed ID: 37259027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.